140 related articles for article (PubMed ID: 15056471)
1. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
Stefanova N; Lundblad M; Tison F; Poewe W; Cenci MA; Wenning GK
Neurobiol Dis; 2004 Apr; 15(3):630-9. PubMed ID: 15056471
[TBL] [Abstract][Full Text] [Related]
2. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Andersson M; Hilbertson A; Cenci MA
Neurobiol Dis; 1999 Dec; 6(6):461-74. PubMed ID: 10600402
[TBL] [Abstract][Full Text] [Related]
3. A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Yoon HH; Kim YH; Shin ES; Jeon SR
J Korean Med Sci; 2014 Nov; 29(11):1555-61. PubMed ID: 25408589
[TBL] [Abstract][Full Text] [Related]
4. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
[TBL] [Abstract][Full Text] [Related]
5. L-dopa response pattern in a rat model of mild striatonigral degeneration.
Kaindlstorfer C; Stefanova N; Garcia J; Krismer F; Döbrössy M; Göbel G; Jellinger K; Granata R; Wenning GK
PLoS One; 2019; 14(6):e0218130. PubMed ID: 31181111
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Carta AR; Frau L; Pontis S; Pinna A; Morelli M
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S165-8. PubMed ID: 18583175
[TBL] [Abstract][Full Text] [Related]
7. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
8. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Ghorayeb I; Fernagut PO; Aubert I; Bezard E; Poewe W; Wenning GK; Tison F
Mov Disord; 2000 May; 15(3):531-6. PubMed ID: 10830420
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
11. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
12. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
13. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
14. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration.
Stefanova N; Mitschnigg M; Ghorayeb I; Diguet E; Geser F; Tison F; Poewe W; Wenning GK
J Neurosci Res; 2004 Oct; 78(1):87-91. PubMed ID: 15372496
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
16. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Carlsson T; Winkler C; Burger C; Muzyczka N; Mandel RJ; Cenci A; Björklund A; Kirik D
Brain; 2005 Mar; 128(Pt 3):559-69. PubMed ID: 15659429
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
19. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
20. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
